Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Akers Biosciences (NASDAQ:AKER) Stock Price

News articles about Akers Biosciences (NASDAQ:AKER) have trended somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Akers Biosciences earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned press coverage about the medical instruments supplier an impact score of 47.6484760279815 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

Shares of Akers Biosciences (NASDAQ AKER) opened at $0.69 on Wednesday. Akers Biosciences has a 1 year low of $0.12 and a 1 year high of $2.90.

Separately, ValuEngine raised shares of Akers Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, December 1st.

WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Akers Biosciences (NASDAQ:AKER) Stock Price” was originally published by Week Herald and is the sole property of of Week Herald. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at

About Akers Biosciences

Akers Biosciences, Inc, together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States and internationally. The company’s marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness.

Insider Buying and Selling by Quarter for Akers Biosciences (NASDAQ:AKER)

Receive News & Ratings for Akers Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply